Skip to Content

Clinical Trials Detail

A Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Intermediate-I, Myelodysplastic Syndrome Patients Based on the International Prognostic Scoring System

Objective
This is a clinical trial of rigosertib that will be administered by mouth which is investigational.
IRB Protocol Number
13-2064
Principal Investigator(s)
DAN POLLYEA

Cancer Trials

  • Leukemia/Myelodysplasia
Sponsor(s)
Onconova
Contact
DEREK SCHATZ at 720-848-0628
or DEREK.SCHATZ@UCDENVER.EDU
Eligibility and Other Participant Information
What To Expect : A screening period to determine eligibility. A treatment period that can last up to 48 weeks. A follow up period will consist of physician contact and clinic visit. // Eligibility criteria include but are not limited to 18 years or older with myelodysplastic syndrome (MDS).